Bachem Holding AGBCHMF 91 EBITDA Margin % is 34.48% as of Dec. 2025, which is 24% above its 10-year median of 27.91. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Bachem Holding AG ranks better than 88.36% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bachem Holding AG's EBITDA for the
six
months ended in Dec. 2025 was $165.3 Mil. Bachem Holding AG's Revenue for the
six
months ended in Dec. 2025 was $479.5 Mil. Therefore, Bachem Holding AG's EBITDA margin for the quarter that ended in Dec. 2025 was 34.48%.
Bachem Holding AG (OTCPK:BCHMF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bachem Holding AG EBITDA Margin % Related Terms
Bachem Holding AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Bachem Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a EBITDA Margin % of 34.48% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bachem Holding AG and its competitors. This is 24% above median its historical median of 27.91. Over the past decade, Bachem Holding AG's EBITDA Margin % has ranged from 26.61 to 31.83. According to the industry distribution chart, Bachem Holding AG ranks #110 out of 945 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Bachem Holding AG's EBITDA Margin % too high?
Bachem Holding AG's current EBITDA Margin % of 34.48% is 24% above median its 10-year median of 27.91. Over the past 10 years, this metric has ranged from a low of 26.61 to a high of 31.83. Based on the distribution chart, Bachem Holding AG ranks #110 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #110 out of 945 companies for EBITDA Margin %. This places Bachem Holding AG in the top 12% of its industry — outperforming the majority of peers. Historically, Bachem Holding AG's own EBITDA Margin % has ranged from 26.61 to 31.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current EBITDA Margin % is 34.48%, which is 24% above median its own 10-year median of 27.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.06, compared to a current price of $87.34 — trading 10.9% below its estimated fair value. The current EBITDA Margin % is 34.48%, which is 24% above median its 10-year median of 27.91. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current EBITDA Margin % is 34.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 10.9% below its estimated GF Value™ of $98.06.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
EBITDA Margin %: 34.48% (24% above median its 10-year median of 27.91)
GF Value™: $98.06 vs. price of $87.34 (10.9% below fair value)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
